Documents
Application Sponsors
BLA 125422 | THROMBOGENICS, INC | |
Marketing Status
Application Products
001 | INJECTABLE; INTRAVITREAL | 2.5MG/ML | 0 | JETREA | OCRIPLASMIN |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2012-10-17 | PRIORITY |
EFFICACY; Efficacy | SUPPL | 25 | AP | 2014-06-13 | PRIORITY |
LABELING; Labeling | SUPPL | 37 | AP | 2016-03-27 | STANDARD |
LABELING; Labeling | SUPPL | 38 | AP | 2017-02-22 | STANDARD |
Submissions Property Types
CDER Filings
THROMBOGENICS, INC
cder:Array
(
[0] => Array
(
[ApplNo] => 125422
[companyName] => THROMBOGENICS, INC
[docInserts] => ["",""]
[products] => [{"drugName":"JETREA","activeIngredients":"OCRIPLASMIN","strength":"2.5MG\/ML","dosageForm":"INJECTABLE; INTRAVITREAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"02\/22\/2017","submission":"SUPPL-38","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/125422s038lbl.pdf\"}]","notes":""},{"actionDate":"03\/27\/2016","submission":"SUPPL-37","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/125422s037lbl.pdf\"}]","notes":""},{"actionDate":"06\/13\/2014","submission":"SUPPL-25","supplementCategories":"Efficacy","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2014\\\/125422s025lbl.pdf\"}]","notes":""},{"actionDate":"10\/17\/2012","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2012\\\/125422s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"10\/17\/2012","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"N\/A","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2012\\\/125422s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2012\\\/125422Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2012\\\/125422_jetrea_toc.cfm\"}]","notes":">"}]
[supplements] => [{"actionDate":"02\/22\/2017","submission":"SUPPL-38","supplementCategories":"Supplement","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/125422s038lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2017\\\/125422Orig1s038ltr.pdf\"}]","notes":">"},{"actionDate":"03\/27\/2016","submission":"SUPPL-37","supplementCategories":"Supplement","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/125422s037lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/125422Orig1s037ltr.pdf\"}]","notes":">"},{"actionDate":"06\/13\/2014","submission":"SUPPL-25","supplementCategories":"Supplement","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2014\\\/125422s025lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2014\\\/125422Orig1s025ltr.pdf\"}]","notes":">"}]
[actionDate] => 2017-02-22
)
)